EPZM Epizyme, Inc. Stock Quote

EPZM [NASD]

Index	-	P/E	-	EPS (ttm)	-2.24	Insider Own	0.20%	Shs Outstand	101.51M	Perf Week	-4.83%
Market Cap	1.16B	Forward P/E	-	EPS next Y	-2.15	Insider Trans	0.49%	Shs Float	82.92M	Perf Month	-9.88%
Income	-221.90M	PEG	-	EPS next Q	-0.59	Inst Own	95.30%	Short Float	12.15%	Perf Quarter	-10.15%
Sales	11.70M	P/S	99.03	EPS this Y	-12.00%	Inst Trans	0.05%	Short Ratio	9.92	Perf Half Y	-17.83%
Book/sh	2.05	P/B	5.72	EPS next Y	4.40%	ROA	-52.70%	Target Price	-	Perf Year	-54.09%
Cash/sh	2.83	P/C	4.14	EPS next 5Y	38.00%	ROE	-83.50%	52W Range	9.90 - 27.82	Perf YTD	7.97%
Dividend	-	P/FCF	-	EPS past 5Y	-3.00%	ROI	-53.70%	52W High	-57.85%	Beta	1.55
Dividend %	-	Quick Ratio	8.70	Sales past 5Y	-10.50%	Gross Margin	72.20%	52W Low	18.43%	ATR	0.64
Employees	203	Current Ratio	8.90	Sales Q/Q	-36.80%	Oper. Margin	-	RSI (14)	47.41	Volatility	4.57% 5.30%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-39.40%	Profit Margin	-	Rel Volume	0.42	Prev Close	11.96
Shortable	Yes	LT Debt/Eq	0.40	Earnings	Nov 06 BMO	Payout	-	Avg Volume	1.02M	Price	11.73
Recom	2.00	SMA20	-1.03%	SMA50	-2.90%	SMA200	-17.79%	Volume	431,281	Change	-1.96%

Dec-21-20

Downgrade

Jefferies

Buy → Hold

$14

Apr-01-20

Downgrade

Oppenheimer

Outperform → Perform

Mar-04-20

Initiated

Barclays

Overweight

$33

Feb-25-20

Reiterated

H.C. Wainwright

Buy

$25 → $36

Jan-24-20

Downgrade

SVB Leerink

Outperform → Mkt Perform

Dec-06-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

May-30-19

Resumed

Citigroup

Buy

Jan-07-19

Upgrade

Leerink Partners

Mkt Perform → Outperform

Sep-07-18

Resumed

Morgan Stanley

Equal-Weight

Jul-03-18

Downgrade

Leerink Partners

Outperform → Mkt Perform

Jan-24-18

Resumed

Jefferies

Buy

$25

Jan-10-18

Initiated

Morgan Stanley

Overweight

$20

Nov-02-17

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$20 → $16

Sep-20-17

Initiated

Jefferies

Buy

$23

May-10-17

Resumed

RBC Capital Mkts

Outperform

$19 → $20

Apr-13-17

Initiated

Oppenheimer

Outperform

May-10-16

Reiterated

Mizuho

Buy

$20 → $18

Apr-05-16

Initiated

Citigroup

Buy

$17

Mar-14-16

Upgrade

H.C. Wainwright

Neutral → Buy

$25

Mar-10-16

Reiterated

Wedbush

Outperform

$33 → $22

Dec-18-20 02:43PM	Is EPZM A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-06-20 11:30AM	Epizyme (EPZM) Down 3.4% Since Last Earnings Report: Can It Rebound? Zacks
Nov-29-20 12:30PM	Billionaire Israel Englander Pours Money Into 2 Strong Buy Stocks TipRanks
Nov-16-20 05:16AM	Carl Goldfischer Is The Independent Director of Epizyme, Inc. (NASDAQ:EPZM) And Just Spent US$60k On Shares Simply Wall St.
Nov-13-20 12:56PM	Insider Buys Epizyme's Shares Benzinga
Nov-11-20 04:05PM	Epizyme to Participate in Jefferies Virtual London Healthcare Conference Business Wire
06:15AM	Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Slashed Next Year's Revenue Estimates By 20% Simply Wall St.
Nov-10-20 05:50AM	Earnings Update: Epizyme, Inc. (NASDAQ:EPZM) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St. +6.38%
Nov-09-20 10:16AM	Epizyme's (EPZM) Q3 Loss Narrower Than Expected, Sales Miss Zacks +10.74%
Nov-08-20 09:24AM	Epizyme, Inc. (NASDAQ:EPZM): Are Analysts Optimistic? Simply Wall St.
Nov-06-20 07:31PM	Epizyme Inc (EPZM) Q3 2020 Earnings Call Transcript Motley Fool -23.69%
07:53AM	Recap: Epizyme Q3 Earnings Benzinga
07:45AM	Epizyme (EPZM) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:30AM	Epizyme Reports Business Progress and Third Quarter 2020 Financial Results Business Wire
06:05AM	Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives Business Wire
06:00AM	Epizyme, Inc. to Host Earnings Call ACCESSWIRE
Oct-30-20 06:30AM	Epizyme Announces Date of Third Quarter 2020 Financial Results Business Wire
Oct-28-20 12:33PM	Epizyme (EPZM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-07-20 03:29PM	Hedge Funds Are Getting Bullish On Epizyme Inc (EPZM) Insider Monkey
06:30AM	Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma Business Wire
Oct-02-20 09:21AM	Reflecting on Epizyme's (NASDAQ:EPZM) Share Price Returns Over The Last Three Years Simply Wall St.
Sep-08-20 06:30AM	Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Sep-03-20 11:31AM	Why Is Epizyme (EPZM) Up 0.6% Since Last Earnings Report? Zacks
Aug-18-20 01:05PM	Is Epizyme (NASDAQ:EPZM) A Risky Investment? Simply Wall St.
Aug-05-20 11:29AM	Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates Zacks +5.93%
Aug-04-20 05:00PM	Epizyme Inc (EPZM) Q2 2020 Earnings Call Transcript Motley Fool -14.41%
07:45AM	Epizyme (EPZM) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:18AM	Recap: Epizyme Q2 Earnings Benzinga
06:30AM	Epizyme Reports Business Progress and Second Quarter 2020 Financial Results Business Wire
Jul-28-20 06:30AM	Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire
Jul-16-20 06:31PM	Were Hedge Funds Right About Epizyme Inc (EPZM)? Insider Monkey
Jun-28-20 09:31AM	Insider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares Simply Wall St.
Jun-20-20 07:57AM	Stock market gives up early gains to end lower as Apple plans to re-close stores and W.H.O. says coronavirus has entered new and dangerous phase MarketWatch
Jun-19-20 10:19AM	Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma Zacks -7.92%
10:02AM	Epizyme's shares fall after receiving new FDA approval for cancer drug MarketWatch
09:41AM	Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock? Zacks
Jun-18-20 01:31PM	Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK (tazemetostat) for Relapsed/Refractory Follicular Lymphoma Business Wire
08:34AM	The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions Benzinga
Jun-17-20 01:56PM	Hedge Funds Arent Done Buying Epizyme Inc (EPZM) Insider Monkey
Jun-16-20 07:09AM	2 Top Cancer Treatment Stocks to Buy in June Motley Fool
Jun-03-20 11:30AM	Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound? Zacks
May-26-20 12:55PM	Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT Thomson Reuters StreetEvents
May-14-20 09:22AM	Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions Zacks
May-13-20 05:12PM	Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program Business Wire
May-07-20 10:51AM	Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses Zacks
May-05-20 09:11AM	Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss Zacks +10.13%
May-04-20 07:00PM	Epizyme Inc (EPZM) Q1 2020 Earnings Call Transcript Motley Fool +5.33%
07:45AM	Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:04AM	Epizyme: Q1 Earnings Insights Benzinga
06:30AM	Epizyme Reports Business Progress and First Quarter 2020 Financial Results Business Wire
Apr-27-20 12:32PM	Earnings Preview: Epizyme (EPZM) Q1 Earnings Expected to Decline Zacks
06:30AM	Epizyme Announces Date of First Quarter 2020 Financial Results Business Wire
Apr-26-20 10:02AM	Is Epizyme, Inc.'s (NASDAQ:EPZM) CEO Overpaid Relative To Its Peers? Simply Wall St.
Apr-19-20 07:02AM	3 Top Biotech Stocks with FDA Approvals on the Horizon TipRanks
Apr-08-20 06:56PM	Is Epizyme Inc (EPZM) A Good Stock To Buy? Insider Monkey +11.83%
Mar-25-20 11:30AM	Epizyme (EPZM) Down 24.9% Since Last Earnings Report: Can It Rebound? Zacks -6.01%
Mar-20-20 06:30AM	Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer Business Wire -6.55%
Mar-06-20 03:41AM	Edited Transcript of EPZM earnings conference call or presentation 24-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-26-20 06:39AM	Epizyme, Inc. Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
Feb-25-20 12:09PM	Analysts: 3 Healthcare Stocks to Buy on Coronavirus Weakness TipRanks
09:38AM	Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat Zacks
09:28AM	Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock? Zacks
05:17AM	Here are the Mass.-based firms hit hardest in Monday's stock rout American City Business Journals
Feb-24-20 07:45AM	Epizyme (EPZM) Reports Q4 Loss, Tops Revenue Estimates Zacks -13.02%
06:30AM	Epizyme, Inc. to Host Earnings Call ACCESSWIRE
06:30AM	Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-23-20 06:38PM	The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace Benzinga
Feb-20-20 08:42AM	Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-19-20 09:21AM	Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
Feb-18-20 06:30AM	Epizyme Announces Date of Fourth Quarter and Full Year 2019 Results and Presentations at Upcoming Investor Conferences Business Wire
Feb-14-20 08:23AM	The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering Benzinga +9.13%
06:30AM	Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK (tazemetostat) for the Treatment of Follicular Lymphoma Business Wire
Feb-12-20 06:55AM	Investors Who Bought Epizyme (NASDAQ:EPZM) Shares Three Years Ago Are Now Up 81% Simply Wall St.
Feb-06-20 05:50PM	Epizyme (EPZM) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-05-20 11:52AM	Steven Cohen Renews His Interest in Verastem GuruFocus.com
Jan-31-20 05:50PM	Epizyme (EPZM) Dips More Than Broader Markets: What You Should Know Zacks
Jan-29-20 09:59AM	Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data Zacks
Jan-24-20 12:00PM	Are You Looking for a Top Momentum Pick? Why Epizyme (EPZM) is a Great Choice Zacks -16.17%
10:44AM	The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study Benzinga
09:57AM	Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma Zacks
05:52AM	Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval Benzinga
Jan-23-20 06:07PM	FDA approves local biotech's first rare-cancer drug American City Business Journals
05:16PM	Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma Business Wire
09:34AM	Axsome (AXSM) Completes Patient Randomization in TRD Study Zacks
09:04AM	Benzinga Pro's Top 5 Stocks To Watch For Thurs., Jan. 23, 2020: CODX, LUV, INTC, PAYC, EPZM Benzinga
Jan-22-20 11:30AM	Is Epizyme (EPZM) Outperforming Other Medical Stocks This Year? Zacks
10:00AM	Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance Zacks
08:57AM	Is the Options Market Predicting a Spike in Epizyme (EPZM) Stock? Zacks
Jan-21-20 09:26AM	Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth Zacks
Jan-20-20 02:04PM	The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings Benzinga
09:32AM	Seattle Genetics Up More Than 40% in the Past Year: Here's Why Zacks
Jan-17-20 08:45AM	ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-09-20 04:47PM	Applied Therapeutics Up on Positive Galactosemia Study Data Zacks
Jan-08-20 12:00PM	What Makes Epizyme (EPZM) a Strong Momentum Stock: Buy Now? Zacks
Jan-07-20 10:26AM	Blueprint Medicines Initiates Dosing in Liver Cancer Study Zacks
09:19AM	aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma Zacks
Jan-06-20 06:30AM	Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value Business Wire
Dec-30-19 09:24AM	3 Healthcare Stocks With Huge FDA Decisions in January TipRanks
Dec-26-19 10:38AM	Epizyme (EPZM) Shares Soar on Lead Candidate's Progress Zacks
Dec-24-19 08:15AM	Will Epizyme Continue to Surge Higher? Zacks

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Agarwal Shefali	Chief Medical Officer	Dec 03	Sale	13.54	2,522	34,148	76,089	Dec 07 07:00 AM
GOLDFISCHER CARL	Director	Nov 11	Buy	12.07	5,000	60,350	5,000	Nov 13 07:05 AM
Beaulieu Joseph	Corporate Controller	Sep 02	Sale	12.88	543	6,994	5,958	Sep 03 09:30 PM
MOTT DAVID M	Director	Jun 26	Buy	16.03	62,019	994,165	82,601	Jun 26 07:12 PM
Beaulieu Joseph	Corporate Controller	Jun 26	Sale	16.15	317	5,120	4,838	Jun 30 09:04 AM
Bazemore Robert B	President & CEO	Jun 26	Sale	16.15	4,773	77,084	250,098	Jun 30 09:01 AM
Agarwal Shefali	Chief Medical Officer	Jun 26	Sale	16.15	1,805	29,151	78,611	Jun 30 08:56 AM
TOMBESI PAOLO	Chief Financial Officer	Jun 26	Sale	16.15	1,805	29,151	21,942	Jun 30 08:57 AM
Ros Matthew	See Remarks	Jun 26	Sale	16.15	2,728	44,057	57,507	Jun 30 08:54 AM
Bazemore Robert B	President & CEO	Jun 18	Option Exercise	8.98	10,000	89,800	264,371	Jun 22 07:36 PM
Ros Matthew	See Remarks	Jun 18	Option Exercise	9.47	112,003	1,060,669	120,449	Jun 22 07:31 PM
Bazemore Robert B	President & CEO	Jun 18	Sale	22.00	20,000	440,000	244,371	Jun 22 07:36 PM
Ros Matthew	See Remarks	Jun 18	Sale	21.24	112,003	2,378,444	51,798	Jun 22 07:31 PM
Beaulieu Joseph	Corporate Controller	Mar 25	Sale	15.28	212	3,239	4,961	Mar 26 09:11 PM
TOMBESI PAOLO	Chief Financial Officer	Mar 25	Sale	15.28	1,243	18,993	15,437	Mar 26 09:01 PM
Ros Matthew	See Remarks	Mar 25	Sale	15.28	1,243	18,993	51,798	Mar 26 09:01 PM
Agarwal Shefali	Chief Medical Officer	Mar 25	Sale	15.28	1,243	18,993	71,991	Mar 26 09:00 PM
Bazemore Robert B	President & CEO	Mar 25	Sale	15.28	3,285	50,195	254,371	Mar 26 09:00 PM
Allen Andrew R	Director	Mar 16	Option Exercise	9.33	12,500	116,625	12,500	Mar 18 04:30 PM
Beaulieu Joseph	Corporate Controller	Mar 03	Sale	22.18	996	22,091	3,617	Mar 05 06:52 PM
Bazemore Robert B	President & CEO	Jan 27	Sale	20.44	6,074	124,153	84,668	Jan 27 09:17 PM
Agarwal Shefali	Chief Medical Officer	Jan 27	Sale	20.44	2,630	53,757	58,803	Jan 27 09:19 PM
Agarwal Shefali	Chief Medical Officer	Jan 24	Sale	24.64	1,843	45,412	61,433	Jan 27 09:19 PM
Bazemore Robert B	President & CEO	Jan 24	Sale	24.62	3,002	73,909	90,742	Jan 27 09:17 PM
Ros Matthew	See Remarks	Jan 24	Sale	24.64	1,847	45,510	42,185	Jan 27 09:18 PM
Beaulieu Joseph	Corporate Controller	Jan 24	Sale	24.63	330	8,128	1,042	Jan 27 09:16 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience